Daré's roy­al­ty deal; Qlaris Bio rais­es $24M

Plus, news about Newron and Syn­Ox:

Daré Bio­science inks roy­al­ty deal with XO­MA: The com­pa­ny re­ceived $22 mil­lion, which is ex­pect­ed to help progress a pair of women’s health ther­a­pies through Phase 3. Dare’s stock $DARE was up about 28% af­ter an­nounc­ing the agree­ment. — Jaimy Lee

Qlaris Bio se­cures $24M in Se­ries B: The pro­ceeds will sup­port the con­tin­ued de­vel­op­ment of the biotech’s Phase 2 as­set, QLS‑111, which is de­signed to low­er in­traoc­u­lar pres­sure in pa­tients with open-an­gle glau­co­ma and oc­u­lar hy­per­ten­sion. The fundraise was co-led by Canaan and New Leaf Ven­ture Part­ners. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER